Navigation Links
China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
Date:6/11/2012

HONG KONG, June 11, 2012 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the fourth quarter and fiscal year ended March 31, 2012.

Fourth Quarter of Fiscal 2012Highlights

  • As a result of the change in operational strategy, fourth quarter new subscribers reached 14,336, a decrease of 8.3%, as compared to 15,641 in the prior year period and up 11.5% from the third quarter of fiscal 2012.
  • Revenues for the fourth quarter of fiscal 2012 increased by 5.4% to RMB99.8 million ($15.8 million) from RMB94.7 million in the prior year period.
  • Gross profit increased by 2.4% to RMB76.4 million ($12.1 million) from RMB74.7 million in the prior year period.
  • Operating profit decreased by 4.4% to RMB34.8 million ($5.5 million) from RMB36.4 million in the prior year period, as a result of enhanced sales force and marketing initiatives for operation expansion.
  • Net income attributable to shareholders increased by 11.3% to RMB29.2 million ($4.6 million) from RMB26.3 million in the prior year period.

  • Full Year of Fiscal 2012 Highlights

  • New subscribers for fiscal 2012 reached 53,924, up 7.8% above our target of 50,000 for the year, as compared to 56,518 in fiscal 2011.
  • Accumulated subscriber base up 29.0% to 239,754.
  • Revenues for the full year of fiscal 2012 increased by 12.1% to RMB380.5 million ($60.4 million) from RMB339.5 million in the prior year.
  • Gross profit increased by 12.1% to RMB293.8 million ($46.7 million) from RMB262.2 million in the prior year.
  • Operating profit increased by 8.9% to RMB134.8 million ($21.4 million) from RMB123.8 million in the prior year.
  • Net income attributable to shareholders increased by 43.9% to RMB132.0 million ($21.0 million) from RMB91.7 million in the prior year.
  • Operating cash flow for fiscal 2012 increased by 100.4% to RMB353.9 million ($56.2 million) from RMB176.6 million in the prior year.

  • "We are pleased by our accomplishments in fiscal year 2012 on several fronts," stated Ms. Ting Zheng, Chairperson and Chief Executive Officer of China Cord Blood Corporation. "For the full year, we exceeded our target of 50,000 new subscribers to add total of 53,924 new subscribers, expanding our total accumulated subscriber base to nearly 240,000. Such growth speaks well for our new marketing strategy, which targets high-end subscribers by offering premium services, and the well-received reception by the market."

    "Furthermore, our new payment model with its emphasis on upfront payments and a higher processing fee per subscriber has strengthened our financial performance," continued Ms. Zheng. "The market's acceptance of this new payment model reinforces our conviction that we have developed a strong foundation for the Company's brand in each region upon which we are successfully expanding China Cord Blood's footprint. In addition to enhancing our strategic positioning, the new payment model has also strengthened our cash flow position as cash generated from operating activities almost doubled in fiscal 2012 from the prior year. All in all, fiscal 2012 concluded with the Company in an outstanding financial position and represented a successful first step towards repositioning our company as a premium healthcare service provider with recognized high-quality services."Summary – The Fourth Quarter and Full Year Ended March 31, 2011 and 2012Three Months Ended

    Twelve Months EndedMarch 31,

    March 31,2011

    2012

    2011

    2012 (in thousands)

    RMB

    RMB

    USD

    RMB

    RMB

    USDRevenues

    94,671

    99,778

    15,844

    339,532

    380,490

    60,419Gross Profit

    74,670

    76,448

    12,139

    262,156

    293,832

    46,658Operating Income

    36,429

    34,842

    5,532

    123,819

    134,843

    21,412Net Income Attributable to Shareholders

    26,259

    29,239

    4,643

    91,703

    131,980

    20,957EPS Attributable to Ordinary Shares
    – Basic and Diluted (RMB/USD)

    0.35

    0.40

    0.06

    1.31

    1.79

    0.28Revenue Breakdown (%)Processing Fee

    78.8%

    74.0%79.1%

    74.0%Storage Fee

    21.2%

    26.0%20.9%

    26.0%New Subscribers (persons)

    15,641

    14,33656,518

    53,924Total Accumulated Subscribers (persons)

    185,830

    239,754185,830

    239,754Summary – Selected Cash Flow Statement ItemsTwelve Months Ended

    March 31, 2011Twelve Months Ended

    March 31, 2012 (in thousands)

    RMBRMB

    USDNet cash provided by operating activities

    176,585353,858

    56,190Net cash used in investing activities

    (33,914)(122,945)

    (19,523)Net cash provided by/(used in) financing activities

    193,141(44,664)

    (7,092)Fourth Quarter Fiscal2012 Financial ResultsREVENUES. Revenues increased by 5.4% to RMB99.8 million ($15.8 million) in the fourth quarter of fiscal 2012 from RMB94.7 million in the prior year period, driven by the higher processing fee per subscriber as well as growth in recurring storage revenue as the Company's accumulated subscriber base continued to expand.

    Revenues generated from storage fees increased to RMB26.0 million ($4.1 million), up 29.4% from RMB20.1 million in the prior year period. Revenue from storage fees accounted for 26.0% of total revenues compared to 21.2% in the prior year period. This shift in revenue mix was driven by persistent growth in accumulated subscribers, which increased by 29.0% year-over-year to 239,754 as a result of continued strong demand from the Beijing and Guangdong markets.

    Revenues generated from processing fees were RMB73.8 million ($11.7 million), down 1.1% from RMB74.6 million in the prior year period, as a result of the decline in new subscriber numbers pursuant to the Company strategy, which was partially offset by the increase in the higher processing fee per subscriber.

    GROSS PROFIT. Gross profit for the fourth quarter of fiscal 2012 increased by 2.4% to RMB76.4 million ($12.1 million) from RMB74.7 million in the prior year period. This reflects a solid gross margin of 76.6% despite the reduction in new subscriber numbers.

    OPERATING INCOME. Operating income for the fourth quarter decreased to RMB34.8 million ($5.5 million) compared to RMB36.4 million in the prior year period, mostly due to an increase in marketing activities and related expenses, operating margin thus decreased to 34.9% as compared to 38.5% in the prior year period. Depreciation and amortization expenses for the fourth quarter were RMB7.7 million ($1.2 million), compared to RMB6.5 million in the prior year period.

    Research and Development Expenses. Research and development expenses increased to RMB2.0 million ($0.3 million) compared to RMB1.7 million in the prior year period as a reflection of the Company's continued focus on technology advancement in relation to cord blood stem cell preservation.

    Sales and Marketing Expenses. Sales and marketing expenses increased by 24.8% to RMB16.6 million ($2.6 million) from RMB13.3 million in the prior year period as the Company continued to invest in promotional initiatives and increased its sales force by 32.2% to better penetrate its growing hospital network and meet increasing subscriber demand. Sales and marketing expenses remained within the management's expectation at 16.6% of revenues in the fourth quarter of fiscal 2012 compared to 14.0% in the prior year period and 17.9% in the third quarter of fiscal 2012.

    General and Administrative Expenses. General and administrative expenses decreased to RMB23.1 million ($3.7 million) compared to RMB23.3 million in the prior year period. General and administrative expenses as a percentage of revenues represented approximately 23.1%, compared to 24.6% in the prior year period and 24.0% in the third quarter of fiscal 2012.

    NET INCOME ATTRIBUTABLE TO SHAREHOLDERS. Despite the decrease in operating income, net income attributable to shareholders for the fourth quarter of fiscal 2012 increased by 11.3% to RMB29.2 million ($4.6 million) from RMB26.3 million in the prior year period, as a result of the preferential tax treatment of a reduced tax rate of 15%, compared to 25% in the prior year period for both Guangdong and Beijing subsidiaries. Net margin for the fourth quarter of fiscal 2012 rose to 29.3% from 27.7% in the prior year period. Basic and diluted earnings per share for the fourth quarter of fiscal 2012 were RMB0.40 ($0.06).

    LIQUIDITY. As of March 31, 2012, the Company had cash and cash equivalents of RMB794.3 million ($126.1 million) compared to RMB611.4 million as of March 31, 2011. The Company had bank loan borrowings of RMB45.0 million ($7.1 million) as of March 31, 2012.

    Full Year Fiscal 2012 Financial ResultsFiscal year 2012 total new subscribers down to 53,924 pursuant the Company strategy to push for higher adoption of upfront payment, but the impact was offset by the increment in processing fee per subscriber from RMB5,000 to RMB5,800. For full year of fiscal 2012, total revenues increased by 12.1% to RMB380.5 million ($60.4 million) from RMB339.5 million in the prior year. The increase was largely attributable to the processing fee increase effective from April 2011 and the expansion of the Company's accumulated subscriber base to 239,754 subscribers. Processing fees and storage fees grew by 4.8% and 39.6%, respectively. Gross profit increased by 12.1% to RMB293.8 million ($46.7 million) from RMB262.2 million in the prior year. Operating income increased by 8.9% to RMB134.8 million ($21.4 million) from RMB123.8 million in the prior year. Net income attributable to shareholders increased by 43.9% to RMB132.0 million ($21.0 million), reflecting solid operational performance and the tax benefits from the Beijing and Guangdong subsidiaries throughout the fiscal year of 2012.

    Basic and diluted earnings per share attributable to ordinary shares were RMB1.79 ($0.28). Fiscal year 2012 net cash provided by operating activities increased to RMB353.9 million ($56.2 million) from RMB176.6 million in the prior year.

    Ms. Zheng concluded, "It has been the Company's strategy to expand our presence both inside and outside of China. With our recently announced partnership with KKR, a globally prominent strategic investor who shares our vision for building China Cord Blood, we believe we are now better enabled to follow through with our long-term expansion strategy. We will continue to seek out appropriate acquisitions targets and partners for cooperation as we develop the Company into a world-leading cord blood banking operator that provides long-term and sustainable returns to our shareholders."

    Conference CallThe Company will host a conference call at 8:00 a.m. ET on Tuesday, June 12, 2012 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the Company's IR website at http://ir.chinacordbloodcorp.com. A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-718-354-1231 or 1-866-519-4004 for US callers or +852-2475-0994 for Hong Kong callers, access code: 80300968.

    About China Cord Blood CorporationChina Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.

    Safe Harbor StatementThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to confirm these statements to actual results, unless required by law.

    The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company's businesses and business environments. These statements reflect the Company's current views with respect to future events and are not a guarantee of future performance. Actual results of the Company's operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People's Republic of China, or PRC; changing legislation or regulatory environments in the PRC; the acceptance by subscribers of the Company's different pricing and payment options and reaction to the introduction of the Company's premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a "reverse merger" with an operating company based in China, as well as general economic conditions; and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission.

    This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the periods ending March 31, 2012 were made at the noon buying rate of RMB6.2975 to $1.00 on March 30, 2012 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

    For more information, please contact:China Cord Blood CorporationMs. Joeling LawTel: (+852) 3605-8180Email: ir@chinacordbloodcorp.com  ICR, Inc.Mr. Rob KoeppTel: (+86) 10-6583-7516U.S. Tel: (646) 405-5185EXHIBIT 1CHINA CORD BLOOD CORPORATIONUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETSAs of March 31, 2011 and 2012

    (in thousands except share data)March 31,March 31,20112012RMBRMBUS$ASSETSCurrent assetsCash and cash equivalents

    611,387794,311126,131Accounts receivable, less allowance for doubtful accounts  (March 31, 2011: RMB11,850; March 31, 2012: RMB13,916)

    77,40279,01212,546Inventories

    6,7296,6661,059Prepaid expenses and other receivables

    9,98211,5611,836Trading securities

    -35456Deferred tax assets

    5,3735,268837Total current assets710,873897,172142,465Property, plant and equipment, net

    250,348267,86242,535Non-current prepayments

    5,7522,863455Non-current accounts receivable, less allowance for doubtful accounts  (March 31, 2011: RMB28,106; March 31, 2012: RMB38,628)

    240,952254,23640,371Inventories

    31,60034,6515,502Intangible assets, net

    134,412129,79120,610Available-for-sale equity securities

    52,73398,19915,593Other investments

    134,363134,36321,336Deferred tax assets

    2,5655,013796Total assets1,563,5981,824,150289,663LIABILITIESCurrent liabilitiesBank loan

    45,00045,0007,146Accounts payable

    5,0466,3431,007Accrued expenses and other payables

    106,73133,3515,296Deferred revenue

    82,319106,11016,850Amounts due to related party

    36036057Income tax payable

    11,1565,943944Total current liabilities250,612197,10731,300Deferred revenue

    162,668306,53448,676Other non-current liabilities

    30,03660,4209,594Deferred tax liabilities

    26,89024,4623,884Total liabilities470,206588,52393,454EXHIBIT 1 (continued)CHINA CORD BLOOD CORPORATIONUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETSAs of March 31, 2011 and 2012 – (continued)

    (in thousands except share data)March 31,March 31,20112012RMBRMBUS$EQUITYShareholders' equityOrdinary shares - US$0.0001 par value, 250,000,000 shares authorized, 75,406,875 sharesand 73,140,147 shares issued and outstanding as of March 31, 2011,and 2012, respectively

    52508Additional paid-in capital

    910,316865,654137,460Accumulated other comprehensive (loss)/ income

    (18,580)26,0574,138Retained earnings

    178,993310,97349,380Total shareholders' equity 1,070,7811,202,734190,986Non-controlling interests22,61132,8935,223Total equity1,093,3921,235,627196,209Total liabilities and equity1,563,5981,824,150289,663EXHIBIT 2CHINA CORD BLOOD CORPORATIONUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSFor the Three Months and Year ended March 31, 2011 and 2012

    (in thousands except per share)Three months ended March 31,Year ended March 31,2011201220112012RMBRMBUS$RMBRMBUS$Revenues

    94,67199,77815,844339,532380,49060,419Direct costs

    (20,001)(23,330)(3,705)(77,376)(86,658)(13,761)Gross profit74,67076,44812,139262,156293,83246,658Operating expensesResearch and development

    (1,717)(1,953)(310)(6,960)(7,615)(1,209)Sales and marketing

    (13,273)(16,567)(2,631)(47,583)(61,678)(9,794)General and administrative

    (23,251)(23,086)(3,666)(83,794)(89,696)(14,243)Total operating expenses

    (38,241)(41,606)(6,607)(138,337)(158,989)(25,246)Operating income36,42934,8425,532123,819134,84321,412Other income, netInterest income

    2,6943,4115429,06513,4322,133Interest expense

    (657)(896)(142)(2,606)(3,287)(522)Exchange (loss)/ gain

    (61)335486(1,343)(213)Dividend income

    ----7,2171,146Others

    2698231311,378737117Total other income, net

    2,2453,3715368,32316,7562,661Income before income tax 38,67438,2136,068132,142151,59924,073Income tax expense

    (10,867)(6,597)(1,048)(33,929)(9,634)(1,530)Net income27,80731,6165,02098,213141,96522,543Income attributable to non-controlling  interests

    (1,548)(2,377)(377)(6,510)(9,985)(1,586)Net income attributable to shareholders26,25929,2394,64391,703131,98020,957Net income per share:Attributable to ordinary shares-Basic

    0.350.400.061.311.790.28-Diluted

    0.350.400.061.311.790.28
    '/>"/>

    SOURCE China Cord Blood Corporation
    Copyright©2012 PR Newswire.
    All rights reserved


    Related biology technology :

    1. China Integrated Energy Inc. Completes Independent Investigation
    2. China Biologic Products Names Chairman David Gao to Additional Post of CEO
    3. China Pharma Holdings, Inc. to Report First Quarter of Fiscal Year 2012 Financial Results on May 15, 2012
    4. China Biologic Has Announced the Resignation of CFO Y. Tristan Kuo and Named Mr. Ming Yang as Interim CFO
    5. China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR
    6. Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region
    7. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
    8. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
    9. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
    10. 3SBio Inc. to Present at the UBS Greater China Conference 2012
    11. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/6/2016)... ... 06, 2016 , ... Contact:, Abby Mitchell, Communications Manager, Phone: ... Sponsors Teacher Training Program , Bite of Science Dinner Event to Strengthen Science ... in Education (CEE) will sponsor a Bite of Science professional enrichment session, cost-free, ...
    (Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
    (Date:2/4/2016)... , Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced today that Edward Lanphier , Sangamo,s president ... the progress of Sangamo,s ZFP Therapeutic ® development ... at 2:40 pm ET on Thursday, February 11, 2016, ... Healthcare Conference. The conference is being held in ...
    (Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
    Breaking Biology Technology:
    (Date:1/7/2016)... Jan. 7, 2016 Various factors have ... products such as biologics and biosimilars. Some of ... healthcare expenditure, growing demand for cost-effective alternatives, growing ... Biosimilars are similar versions of their corresponding patented ... their quality, safety, and efficacy. The global biosimilars ...
    (Date:1/6/2016)... Calif. , Jan. 6, 2016  Varam Capital, ... as their trusted partner to deliver advanced authentication solutions ... financial services to the poor. A loan of a ... their lives, giving them the ability to purchase livestock ... to make clothing, or stock for a local store. ...
    (Date:1/6/2016)...   A&D Medical , a global leader in ... be unveiling a new line of personal mobile health ... UltraConnect – at CES 2016, with the introduction of its ... monitors. ... upper arm wireless blood pressure monitors represent the launch ...
    Breaking Biology News(10 mins):